IO Biotech, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mai-Britt Zocca
- Full Time Employees
- 80
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Ole Maaløes Vej 3 Copenhagen Denmark 2200
- IPO Date
- Nov 5, 2021
- CIK
- 0001865494
- Website
- iobiotech.com
- Similar Companies
- Business
- IO Biotech Inc (Nasdaq: IOBT), a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Copenhagen, Denmark, develops immune-modulating therapeutic cancer vaccines based on its proprietary T-win platform targeting the tumor microenvironment. The company's lead product candidate, Cylembio (IO102-IO103; imsapepimut and etimupepimut, adjuvanted), is a dual-antigen vaccine designed to activate T cells against IDO1+ and PD-L1+ immunosuppressive cells as well as tumor cells; it is in Phase 3 development (IOB-013/KN-D18) in combination with pembrolizumab for first-line advanced melanoma, Phase 2 trials for non-small cell lung cancer (IOB-022) and squamous cell carcinoma of the head and neck (IOB-032), with additional evaluation in other solid tumors. The pipeline also includes earlier-stage candidates such as IO112 targeting arginase 1 and IO170 targeting TGF-β1 for solid tumors, leveraging the T-win platform to generate off-the-shelf vaccines that modulate the tumor microenvironment, enhance pro-inflammatory conditions, and improve anti-tumor activity without systemic toxicity; operations span global clinical trials with contract manufacturing and research organizations, serving patients with hard-to-treat cancers through combination immunotherapy approaches. In 2025, IO Biotech reported Phase 3 topline results for Cylembio plus pembrolizumab in first-line advanced melanoma demonstrating clinically meaningful progression-free survival improvement (median 19.4 months versus 11.0 months, HR 0.77, p=0.0558) across the overall population and key subgroups including PD-L1-negative patients, though narrowly missing statistical significance on the primary endpoint; the company is pursuing FDA discussions for a potential new registrational trial, presented preclinical data for IO112 and IO170 at SITC showing T-cell activation, tumor growth inhibition, and metastasis reduction, secured a second €12.5 million tranche from its European Investment Bank loan facility, and announced a 50% workforce reduction restructuring incurring $1.0-$1.5 million in charges to extend cash runway into Q1 2026.
IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from Analysts
Analysts Set IO Biotech, Inc. (NASDAQ:IOBT) PT at $6.33
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Grows By 47.2%
IO Biotech Provides Corporate Update
IO Biotech Announces Exploration of Strategic Alternatives
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
IO Biotech Announces Participation in Upcoming December Investor Conferences
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why
IO Biotech, Inc. (NASDAQ:IOBT) Receives Average Rating of “Hold” from Analysts
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know